{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-329511","form_type":"8-K","ticker":"DYN","cik":"0001818794","company_name":"Dyne Therapeutics, Inc.","filed_at":"2025-12-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.585123+00:00","generated_at":"2026-05-16T12:17:03.794818+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Dyne Therapeutics elects Vikram Karnani as Class II director effective Dec 22, 2025","bullets":["Vikram Karnani elected to the Board as an independent director; term expires at 2028 Annual Meeting.","Received option to purchase 59,665 shares at $20.78/share, vesting monthly over three years.","Will receive annual cash compensation of $45,000 plus standard equity grants under non-employee director plan.","No family relationships or material transactions with the Company; standard indemnification agreement entered."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-329511","json":"https://secwatch.observer/filing/0001193125-25-329511.json","markdown":"https://secwatch.observer/filing/0001193125-25-329511.md","text":"https://secwatch.observer/filing/0001193125-25-329511.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818794/000119312525329511/0001193125-25-329511-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818794/000119312525329511/dyn-20251222.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:17:03.794818+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}